Key facts
- This page summarizes Robert Nelsen's Form 4 filing for CITY THERAPEUTICS, INC. (CTY).
- 8 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 19 Oct 2026, 17:37.
Robert Nelsen - 15 Oct 2026 Form 4 Insider Report for CITY THERAPEUTICS, INC. (CTY)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- CTY
- Reported as of
- 15 Oct 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Oct 2026, 17:37:43 UTC
- Prior SEC filing
- 08 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mary Beth DeLena, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Robert Nelsen filed Form 4 for CITY THERAPEUTICS, INC. (CTY) on 19 Oct 2026.
Change
- Previous filing in this sequence was filed on 08 Jun 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001219042
Primary reporting owner
NELSEN ROBERT
- Relationship
- Director, 10%+ Owner
- Address
- 399 BINNEY STREET, CAMBRIDGE
- Signature
- /s/ Mary Beth DeLena, as Attorney-in-Fact
- Signature date
- 19 Oct 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CTY
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +3,294,900
- Change %
- +121%
- Price
- Shares after
- 6,013,192
- Date
- 19 Oct 2026
- Ownership
- By ARCH Venture Fund XII, L.P.
- Footnotes
- F1, F2
CTY
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +5,482,309
- Change %
- +91%
- Price
- Shares after
- 11,495,501
- Date
- 19 Oct 2026
- Ownership
- By ARCH Venture Fund XII, L.P.
- Footnotes
- F1, F2
CTY
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +2,027,006
- Change %
- +18%
- Price
- Shares after
- 13,522,507
- Date
- 19 Oct 2026
- Ownership
- By ARCH Venture Fund XII, L.P.
- Footnotes
- F1, F2
CTY
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +170,000
- Change %
- +1.3%
- Price
- $18.00*
- Shares after
- 13,692,507
- Date
- 19 Oct 2026
- Ownership
- By ARCH Venture Fund XII, L.P.
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CTY
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +22,649
- Change %
- Price
- $0.000000*
- Shares after
- 22,649
- Date
- 15 Oct 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,649
- Exercise price
- $18.00
- Footnotes
- F3
CTY
transaction
Derivative
Series Seed convertible preferred stock
Conversion of derivative security
- Transaction value
- Shares
- -3,000,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 19 Oct 2026
- Ownership
- By ARCH Venture Fund XII, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 3,294,900
- Exercise price
- Footnotes
- F1, F2
CTY
transaction
Derivative
Series A convertible preferred stock
Conversion of derivative security
- Transaction value
- Shares
- -4,991,633
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 19 Oct 2026
- Ownership
- By ARCH Venture Fund XII, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 5,482,309
- Exercise price
- Footnotes
- F1, F2
CTY
transaction
Derivative
Series B convertible preferred stock
Conversion of derivative security
- Transaction value
- Shares
- -1,845,585
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 19 Oct 2026
- Ownership
- By ARCH Venture Fund XII, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 2,027,006
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each share of Series Seed convertible preferred stock, Series A convertible preferred stock and Series B convertible preferred stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-to-1.0983 basis at the option of the holder, and automatically converted into Common Stock upon the closing of the Issuer's initial public offering on October 19, 2026 without payment of consideration. The Preferred Stock had no expiration date.
Footnote F2
Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein, if any.
Footnote F3
The shares underlying this option vest in full upon the earlier of (i) October 15, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.